GSK notifies availability of ViiV Healthcare AIDS 2026 data presentation announcement

GSK posted a press release on ViiV Healthcare HIV data slated for AIDS 2026.

Highlights include phase IIIb VOGUE head-to-head results comparing Dovato with Gilead’s Biktarvy in treatment-naïve adults.

The update also flags new real-world OPERA findings for Cabenuva, GSK’s long-acting injectable HIV regimen.